Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POPular AGE: Clopidogrel vs Ticagrelor/Prasugrel in Elderly ACS
NCT02317198Phase 4Completed
- Start
- Jun 2013
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of clopidogrel in Non-ST-elevation acute coronary syndrome (NSTE-ACS) (2 arms). Primary endpoints: Occurrence of any bleeding episode requiring medical intervention at 1 year and Net clinical benefit (all cause mortality, non-fatal myocardial infarction, non-fatal stroke, PLATO major and minor bleeding) at 1 year. Started Jun 2013; status: completed.
02
Drugs
clopidogrel
03
Conditions
Non-ST-elevation acute coronary syndrome (NSTE-ACS)
Beyond the preview
Go deeper on NCT02317198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02317198.